Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy

Abstract

Aim: Co-encapsulation of anti-cancer agents in pegylated liposomes may provide an effective tool to maximize efficacy of combined drug therapy by taking advantage of the long circulation time, passive targeting, and reduced toxicity of liposome formulations.

Methods: We have developed several liposome formulations of co-encapsulated drugs using various permutations of three active agents: doxorubicin (Dox), mitomycin-C lipidic prodrug (MLP), and alendronate (Ald). Dox and MLP are available in single drug liposomal formulations: pegylated liposomal Dox (PLD, Doxil®), clinically approved, and pegylated liposomal MLP (PL-MLP, Promitil®), in phase 1-2 clinical testing. We have previously shown that co-encapsulation of Dox and Ald in pegylated liposomes (PLAD) results in a formulation with valuable immuno-pharmacologic properties and superior antitumor properties over PLD in immunocompetent animal models. Building on the PLAD and PL-MLP platforms, we developed a new pegylated liposomal formulation of co-entrapped Dox and MLP (PLAD-MLP), with the former localized in the liposome water phase via remote loading with an ammonium alendronate and the latter passively loaded into the liposome lipid bilayer. An alternative formulation of co-entrapped MLP and Dox in which ammonium Ald was replaced with ammonium sulfate (PLD-MLP) was also tested for comparative purposes.

Results: PLAD-MLP displays high loading efficiency of Dox and MLP nearing 100%, and a mean vesicle diameter of 110 nm. Cryo-transmission electron microscopy (cryo-TEM) of PLAD-MLP reveals round vesicles with an intra-vesicle Dox-alendronate precipitate. PLAD-MLP was tested in an in vitro MLP activation assay with the reducing agent dithiothreitol and found to be significantly less susceptible to thiolytic activation than PL-MLP. Alongside thiolytic activation of MLP, a significant fraction of encapsulated Dox was released from liposomes. PLAD-MLP is stable upon in vitro incubation in human plasma with nearly 100% drug retention. In mouse pharmacokinetic studies, PLAD-MLP extended MLP half-life in circulation when compared to that of MLP delivered as PL-MLP. In addition, the MLP levels in tissues were greater than those obtained with PL-MLP, indicating that PLAD-MLP slows down the cleavage of the prodrug MLP to MMC, thus resulting in a more sustained and prolonged exposure. The circulation half-life of Dox in PLAD-MLP was similar to the PLD Dox half-life. The pattern of tissue distribution was similar for the co-encapsulated drugs, although Dox levels were generally higher than those of MLP, as expected from cleavage of MLP to its active metabolite MMC. In mouse tumor models, the therapeutic activity of PLAD-MLP was superior to PL-MLP and PLD with a convenient safety dose window. The Ald-free formulation, PLD-MLP, displayed similar pharmacokinetic properties to PLAD-MLP, but its therapeutic activity was lower.

Conclusion: PLAD-MLP is a novel multi-drug liposome formulation with attractive pharmacological properties and powerful antitumor activity and is a promising therapeutic tool for combination cancer chemotherapy.

Keywords

Doxorubicin / mitomycin c / prodrug / bisphoshonate / drug delivery / drug carrier / nanoparticle / remote loading

References

[1] Franco MS.Liposomes co- encapsulating anticancer drugs in synergistic ratios as an approach to promote increased efficacy and greater safety..Anticancer Agents Med Chem2019;19:17-28

[2] Tolcher AW.Improving combination cancer therapy: the CombiPlex(®) development platform..Future Oncol (London, England)2018;14:1317-32

[3] Lancet JE,Cortes JE.CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia..J Clin oncol2018;36:2684-92 PMCID:PMC6127025

[4] Shmeeda H,Gorin J.Coencapsulation of alendronate and doxorubicin in pegylated liposomes: a novel formulation for chemoimmunotherapy of cancer..J Drug Target2016;24:878-89

[5] Hodgins NO,Al-Jamal KT.Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of γδ T cells for anticancer immunotherapy..Adv Drug Deliv Rev2017;114:143-60

[6] La-Beck NM,Shmeeda H,Gabizon AA.Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment..Semin Cancer Biol2019;

[7] Luo S,Zhang Y.Precise ratiometric control of dual drugs through a single macromolecule for combination therapy..Mol Pharm2015;12:2318-27

[8] Cheung RY,Ronaldson PT,Wu XY.In vitro toxicity to breast cancer cells of microsphere-delivered mitomycin C and its combination with doxorubicin..Eur J Pharm Biopharm2006;62:321-31

[9] Cheung RY,Yu Wu X.In vivo efficacy and toxicity of intratumorally delivered mitomycin C and its combination with doxorubicin using microsphere formulations..Anticancer Drugs2005;16:423-33

[10] Maitra R,Karlson KH.Differential effects of mitomycin C and doxorubicin on P-glycoprotein expression..Biochem J2001;355:617-24 PMCID:PMC1221775

[11] Ihnat MA,Warren AJ.Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents..Clin Cancer Res1997;3:1339-46

[12] Ihnat MA,Anthony SP.Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice..Oncol Res1999;11:303-10

[13] Shuhendler AJ,Rauth AM.On the synergistic effect of doxorubicin and mitomycin C against breast cancer cells..Drug Metabol Drug Interact2007;22:201-33

[14] Shuhendler AJ,Manias J,Rauth AM.A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells..Breast Cancer Res Treat2010;119:255-69

[15] Prasad P,Shuhendler A,Wu XY.A novel nanoparticle formulation overcomes multiple types of membrane efflux pumps in human breast cancer cells..Drug Deliv Transl Res2012;2:95-105

[16] Shuhendler AJ,Zhang RX.Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model..Mol Pharm2014;11:2659-74

[17] Prasad P,Cai P,Wu XY.Doxorubicin and mitomycin C co-loaded polymer-lipid hybrid nanoparticles inhibit growth of sensitive and multidrug resistant human mammary tumor xenografts..Cancer Lett2013;334:263-73

[18] Gabizon A,Tahover E.Development of Promitil®, a lipidic prodrug of mitomycin c in PEGylated liposomes: from bench to bedside..Adv Drug Deliv Rev2020;154-155:13-26

[19] Amitay Y,Patil Y.Pharmacologic studies of a prodrug of mitomycin C in pegylated liposomes (Promitil®): high stability in plasma and rapid thiolytic prodrug activation in tissues..Pharm Res2016;33:686-700

[20] Golan T,Ohana P.Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients..Cancer Med2015;4:1472-83 PMCID:PMC4618618

[21] Patil Y,Amitay Y,Kumar S.Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA)..Nanomedicine2018;14:1407-16

[22] Gabizon A,Cohen R.Development of liposomal anthracyclines: from basics to clinical applications..J Control Release1998;53:275-9

[23] Wei X,Ohana P.Characterization of pegylated liposomal mitomycin c lipid-based prodrug (Promitil) by high sensitivity differential scanning calorimetry and cryogenic transmission electron microscopy..Mol Pharm2017;14:4339-45

[24] Beheshti A,Farahani H.Determination of cholesterol and its derivatives in nanoliposomes as drug delivery conveyances by HPLC-UV: a simple, accurate and cost-effective method development and validation approach..J Chromatogr Sci2019;57:469-75

[25] Patil Y,Ohana P,Gabizon A.Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity..J Control Release2016;225:87-95

[26] Gabizon A,Mak L,Horowitz AT.Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models..J Drug Target2002;10:539-48

[27] Wei X,Barenholz Y.Insights into composition/structure/function relationships of Doxil® gained from “high-sensitivity” differential scanning calorimetry..Eur J Pharm Biopharm2016;104:260-70

[28] Gabizon AA,La-Beck NM.New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy..Drug Resist Updat2016;29:90-106

[29] Peretz Damari S,Varenik M.Practical aspects in size and morphology characterization of drug-loaded nano-liposomes..Int J Pharm2018;547:648-55

[30] Schilt Y,Wei X,Raviv U.Using solution X-ray scattering to determine the high-resolution structure and morphology of PEGylated liposomal doxorubicin nanodrugs..Biochim Biophys Acta2016;1860:108-19

[31] Horowitz AT,Gabizon AA.In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release..Biochim Biophys Acta1992;1109:203-9

[32] Gabizon AA,La-Beck NM.Translational considerations in nanomedicine: the oncology perspective..Adv Drug Deliv Rev2020;158:140-57

[33] Gabizon AA,Horowitz AT,Yeh J.Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes..Clin Cancer Res2006;12:1913-20

[34] Gabizon A,Tzemach D,Goren D.Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines..J Drug Target1996;3:391-8

[35] Goren D,Tzemach D,Zalipsky S.Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump..Clin Cancer Res2000;6:1949-57

[36] Alfayez M,Kadia T,Daver N.CPX-351 (vyxeos) in AML..Leuk Lymphoma2020;61:288-97

[37] Feldman EJ,Kolitz JE.First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia..J Clin Oncol2011;29:979-85 PMCID:PMC4520927

[38] Zhang RX,Zhang T.Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor..Nanomedicine2016;12:1279-90

[39] Golombek SK,Theek B.Tumor targeting via EPR: strategies to enhance patient responses..Adv Drug Deliv Rev2018;130:17-38 PMCID:PMC6130746

[40] Doyle LA,Carney DN.Combination chemotherapy with doxorubicin and mitomycin C in non small cell bronchogenic carcinoma: Severe pulmonary toxicity from q 3 weekly mitomycin C..Am J Clin Oncol1984;7:719-24

[41] Flaumenhaft R.Vascular thiol isomerases..Blood2016;128:893-901 PMCID:PMC4990854

[42] Toy R,Shoup C,Karathanasis E.The effects of particle size, density and shape on margination of nanoparticles in microcirculation..Nanotechnology2011;22:115101 PMCID:PMC3530262

[43] Zocchi MR,Benelli R.Cancer nanomedicine special issue review anticancer drug delivery with nanoparticles: extracellular vesicles or synthetic nanobeads as therapeutic tools for conventional treatment or immunotherapy..Cancers (Basel)2020;12:1886 PMCID:PMC7409190

[44] Gabizon A,Tzemach D,Shmeeda H.Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models..J Control Release2012;160:245-53

[45] Rios-Doria J,Wetzel L.Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models..Neoplasia (New York, NY)2015;17:661-70 PMCID:PMC4674486

[46] Edmonds S,Shmeeda H.Exploiting the metal-chelating properties of the drug cargo for in vivo positron emission tomography imaging of liposomal nanomedicines..ACS Nano2016;10:10294-307 PMCID:PMC5121927

[47] Gawne P,Fonslet J.Manganese-52: applications in cell radiolabelling and liposomal nanomedicine PET imaging using oxine (8-hydroxyquinoline) as an ionophore..Dalton Trans2018;47:9283-93 PMCID:PMC6049564

[48] Man F,Volpe A.In Vivo PET tracking of (89)Zr-Labeled Vgamma9Vdelta2 T cells to mouse xenograft breast tumors activated with liposomal alendronate..Mol Ther2019;27:219-29 PMCID:PMC6318719

[49] Rajan R,Mavinkurve V.Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate..J Control Release2018;271:139-48 PMCID:PMC5880305